十一月 2025
- Home
- Allogene Therapeutics, Inc.
十一月 2025的Allogene Therapeutics, Inc.市场份额分析
REDEFINING THE FUTURE OF CELL THERAPY WITH OUR AlloCAR T™ PRODUCT PLATFORM INNOVATION Multiplex gene-engineering and gene-editing capabilities Proprietary lymphodepletion platform State-of-the-art manufacturing Opportunity for product optimization SEE OUR PIONEERING PLATFORM >> KEY PROGRAMS Cemacabtagene ansegedleucel (cema-cel): Frontline treatment in LBCL, including diffuse large B-cell lymphoma (DLBCL) ALLO-316: ccRCC ALLO-329: autoimmune disease EXPLORE OUR PIPELINE >> LEADERSHIP A […]
Allogene Therapeutics, Inc.(包含公司地区分支机构)
查看更多网站流量和参与度信息- allogene.com
Allogene Therapeutics, Inc.收入截至 十一月 2025为 25M - 50M
Allogene Therapeutics, Inc.主要域名产生的收入
3 年中Allogene Therapeutics, Inc.主要域名的收入
Allogene Therapeutics, Inc.主要域名的收入
Allogene Therapeutics, Inc.热门域名的总访问量
了解Allogene Therapeutics, Inc.市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Allogene Therapeutics, Inc.热门域名的平均访问时长
分析Allogene Therapeutics, Inc.参与度指标。
过去 3 个月的平均访问时长
子公司明细
Allogene Therapeutics, Inc.热门域名的平均页面浏览量
了解Allogene Therapeutics, Inc.如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Allogene Therapeutics, Inc. 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Allogene Therapeutics Inc attends event ASH Annual Meeting.Allogene Therapeutics announces ALPHA3 Trial-in-Progress poster presentation at ASH Annual Meeting.
十一月 3, 2025阅读更多
新闻Allogene Therapeutics Inc attends event 2025 Biopharma Back to School Summit.Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T(TM) therapies for cancer and autoimmune diseases, has announced its participation in Citi's 2025 Biopharma Back to School Summit.
八月 27, 2025阅读更多
新闻David D. Chang leaves Allogene Therapeutics Inc as President, Chief Executive Officer & Director.Dr. David D. Chang is a President, Chief Executive Officer & Director at Allogene Therapeutics, Inc., a Director & Venture Partner at Vida Ventures LLC, a Venture Partner at Two River Consulting LLC, a Board Observer at Cell Design Labs, Inc., a Venture Partner at Two River Group Holdings LLC and a Venture Partner at VV Manager LLC.
三月 3, 2025阅读更多
查看 Allogene Therapeutics, Inc. 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。